AbCellera Biologics

AbCellera is a technology company that searches and analyzes natural immune systems to find antibodies that can be developed as drugs. Its AI-powered platform integrates deep single-cell screening with proprietary microfluidics technology, bioinformatics, and high-throughput assays to accelerate antibody drug discovery. AbCellera gained prominence for its role in rapidly identifying bamlanivimab, the first monoclonal antibody treatment authorized by the FDA for COVID-19, going from a patient blood sample to clinical trial in just 90 days.

$555M+ (IPO)

Total raised

Full-stack antibody drug discovery platform combining microfluidics-based single B cell screening with AI/ML analysis to rapidly identify therapeutic antibody candidates from natural immune responses.